Home>>Signaling Pathways>> Proteases>> Aminopeptidase>>LTA4H-IN-1

LTA4H-IN-1

Catalog No.GC63435

LTA4H-IN-1 is a potent inhibitor of leukotriene A4 hydrolase (LTA4H) extracted from patent WO2015092740A1, example 29, has an IC50 of 2 nM.

Products are for research use only. Not for human use. We do not sell to patients.

LTA4H-IN-1 Chemical Structure

Cas No.: 1799681-85-8

Size Price Stock Qty
10mM (in 1mL DMSO)
$248.00
In stock
5 mg
$225.00
In stock
10 mg
$360.00
In stock
25 mg
$702.00
In stock
50 mg
$1,125.00
In stock
100 mg
$1,755.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

LTA4H-IN-1 is a potent inhibitor of leukotriene A4 hydrolase (LTA4H) extracted from patent WO2015092740A1, example 29, has an IC50 of 2 nM. LTA4H-IN-1 can be used for the research of inflammatory and autoimmune disorders[1].

LTA4H-IN-1 (15 min) inhibits the hydrolysis of 7-amino-4-methylcoumarin (AMC) derivative of Arginine (Arg-AMC) which is catalyzed by LTA4H, with an IC50 of 2 nM[1].LTA4H-IN-1 (30 min) inhibits LTB4 biosynthesis in a human whole blood assay (hWB), with an IC50 of 167 nM[1].

LTA4H-IN-1 (0.3 mg/kg; a single p.o.) inhibits the -43% release of LTB4 compared with vehicle control in mice[1].

[1]. Bollbuck B, et, al. Heteroaryl butanoic acid derivatives as leukotriene A4 hydrolase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases. WO2015092740A1.

Reviews

Review for LTA4H-IN-1

Average Rating: 5 ★★★★★ (Based on Reviews and 34 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for LTA4H-IN-1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.